tiprankstipranks
Compugen Ltd (CGEN)
NASDAQ:CGEN
Holding CGEN?
Track your performance easily

Compugen (CGEN) Earnings Date & Reports

962 Followers

Earnings Data

Report Date
Feb 20, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
$0.07
Last Year’s EPS
$0.11
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 12, 2024
|
% Change Since: -12.07%
|
Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant financial improvements and promising clinical data, particularly for COM701 and COM503. However, there remain challenges in treating platinum-resistant ovarian cancer and in refining biomarker strategies. The company's partnerships and development plans indicate a positive outlook.
Company Guidance
During Compugen's Q3 2024 earnings call, the company provided detailed guidance on its development strategy and financial outlook. Compugen plans to advance COM701 as a monotherapy in a relapsed platinum-sensitive ovarian cancer maintenance setting, aiming to initiate a trial in Q2 2025 with interim data expected by H2 2026. The trial will start with 60 patients, using a 2:1 randomization to COM701 or placebo, with a primary endpoint of median progression-free survival, targeting a benchmark of approximately 6 months in the placebo group. The company anticipates having a cash runway into 2027, supported by a $113.2 million cash position as of September 30, 2024, and no debt. Compugen also highlighted a $30 million milestone payment received from Gilead for achieving FDA IND clearance for COM503, and it expects to begin a Phase I study shortly. The company projects potential key catalysts within this cash runway and continues to explore biomarker strategies to enhance patient selection and treatment efficacy.
Strong Financial Position
Cash balance as of September 30, 2024, was approximately $113.2 million, compared to $51.1 million at the end of 2023, providing a cash runway expected to fund current plans into 2027.
Significant Revenue Increase
Q3 2024 revenues were $17.1 million, compared to no revenues in Q3 2023, driven by a $30 million milestone payment from Gilead.
Encouraging Clinical Data for COM701
COM701 showed a 17% objective response rate and a 46% disease control rate in platinum-resistant ovarian cancer patients, with a favorable safety profile and durable responses.
Promising Development of COM503
Received $30 million milestone payment from Gilead for achieving FDA IND clearance, with plans to initiate Phase I study in the current quarter.
Potential Revenue from AstraZeneca Partnership
AstraZeneca's broad development strategy with Rilvegostomig, which includes components derived from COM902, may provide significant future revenue, including milestone payments and royalties.
---

Compugen (CGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CGEN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 20, 20252024 (Q4)
0.07 / -
0.11
Nov 12, 20242024 (Q3)
-0.10 / 0.01
-0.11109.09% (+0.12)
Aug 06, 20242024 (Q2)
-0.09 / -0.02
-0.1181.82% (+0.09)
May 20, 20242024 (Q1)
-0.11 / -0.08
-0.1127.27% (+0.03)
Mar 05, 20242023 (Q4)
0.10 / 0.11
-0.04375.00% (+0.15)
Nov 07, 20232023 (Q3)
-0.10 / -0.11
-0.1421.43% (+0.03)
Aug 07, 20232023 (Q2)
-0.12 / -0.11
-0.110.00% (0.00)
May 15, 20232023 (Q1)
-0.12 / -0.11
-0.110.00% (0.00)
Feb 27, 20232022 (Q4)
-0.14 / -0.04
-0.160.00% (+0.06)
Nov 14, 20222022 (Q3)
-0.12 / -0.14
-0.07-100.00% (-0.07)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

CGEN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2024$1.74$1.60-8.05%
Aug 06, 2024$1.64$1.72+4.88%
May 20, 2024$2.11$1.74-17.54%
Mar 05, 2024$2.95$2.55-13.56%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Compugen Ltd (CGEN) report earnings?
Compugen Ltd (CGEN) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
    What is Compugen Ltd (CGEN) earnings time?
    Compugen Ltd (CGEN) earnings time is at Feb 20, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CGEN EPS forecast?
          CGEN EPS forecast for the fiscal quarter 2024 (Q4) is $0.07.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis